We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IQV:NYSEIQVIA Holdings, Inc. analysis

Data as of Sep 27, 2026 - not real-time

Latest price
$270.37
Risk: medium
5/10Medium risk

Summary

IQVIA Holdings Inc. is priced at $270.37 and its moving averages line up in bullish order, the shorter sitting above the longer. Over a rolling month the price has gained 11.9%. Momentum indicators put RSI at 60.6 (approaching overbought) with MACD reading bearish. The recent range runs from support at $252.53 up to resistance at $277.40.
Multiples put this in overvalued territory: 33.7 times earnings against the sector's 30.5. Revenue is growing at 8.7% on a 8.1% profit margin.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 25.8%, a beta of 0.77 and a maximum drawdown of 35.9%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.

Top market events

  • IQVIA Holdings stock is trading above $260 after a strong second-quarter 2026 earnings beat, double-
  • IQVIA Holdings stock trades in a bullish technical trend as of September 14, 2026, while Q2 2026 gui
  • IQVIA Holdings has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the...

Market outlook

Short term

< 1 year

Neutral

Model confidence3/103 out of 10

Key factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 204.76
  • MACD momentum is negative

Medium term

1–3 years

Neutral

Model confidence2/102 out of 10

Key factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 33.7 versus sector average of 30.5
  • Trading above the 200-day average of 204.76

Long term

> 3 years

Neutral

Model confidence1/101 out of 10

Key factors

  • P/E of 33.7 versus sector average of 30.5
  • Return on equity of 22.8%
  • Elevated debt-to-equity of 258

Key metrics

Financial health

Revenue Growth8.70%
Profit Margin8.10%
P/E Ratio33.7
ROE22.82%
ROA5.06%
Debt/Equity257.98
P/B Ratio7.2
Op. Cash Flow$2.8B
Free Cash Flow$2.1B
Industry P/E30.5

Technical analysis

TrendBullish
RSI60.6
Support$252.53
Resistance$277.40
MA 20$265.65
MA 50$247.59
MA 200$204.76
MACDBearish
VolumeIncreasing
Fear & Greed Index94.88

Valuation

Fair Value$139.51
Target Price$277.94
Upside/Downside2.80%
GradeOvervalued
TypeGrowth

Risk assessment

Beta0.77
Volatility25.84%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.